These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 33640910)
1. Berberine reduces circulating inflammatory mediators in patients with severe COVID-19. Zhang BY; Chen M; Chen XC; Cao K; You Y; Qian YJ; Yu WK Br J Surg; 2021 Jan; 108(1):e9-e11. PubMed ID: 33640910 [No Abstract] [Full Text] [Related]
2. The role of berberine in Covid-19: potential adjunct therapy. Babalghith AO; Al-Kuraishy HM; Al-Gareeb AI; De Waard M; Al-Hamash SM; Jean-Marc S; Negm WA; Batiha GE Inflammopharmacology; 2022 Dec; 30(6):2003-2016. PubMed ID: 36183284 [TBL] [Abstract][Full Text] [Related]
3. COVID-19: Some clinical questions after the first 4 months. Bassetti M; Ansaldi F; Icardi G; Pelosi P; Robba C; Taramasso L; Trucchi C; Vena A; Giacobbe DR Eur J Clin Invest; 2020 Jul; 50(7):e13326. PubMed ID: 32562550 [No Abstract] [Full Text] [Related]
4. Comprehensive Landscape of Heparin Therapy for COVID-19. Shi C; Tingting W; Li JP; Sullivan MA; Wang C; Wang H; Deng B; Zhang Y Carbohydr Polym; 2021 Feb; 254():117232. PubMed ID: 33357843 [TBL] [Abstract][Full Text] [Related]
5. Rapid evolution of our understanding of the pathogenesis of COVID-19: Implications for therapy. Mustafa F; Giles R; Pepper MS S Afr Med J; 2020 Oct; 110(12):1180-1185. PubMed ID: 33403962 [TBL] [Abstract][Full Text] [Related]
6. Can Natural Polyphenols Help in Reducing Cytokine Storm in COVID-19 Patients? Giovinazzo G; Gerardi C; Uberti-Foppa C; Lopalco L Molecules; 2020 Dec; 25(24):. PubMed ID: 33322757 [TBL] [Abstract][Full Text] [Related]
7. Can Resveratrol-Inhaled Formulations Be Considered Potential Adjunct Treatments for COVID-19? Rossi GA; Sacco O; Capizzi A; Mastromarino P Front Immunol; 2021; 12():670955. PubMed ID: 34093569 [TBL] [Abstract][Full Text] [Related]
8. Purposing Saikosaponins for the treatment of COVID-19. Bahbah EI; Negida A; Nabet MS Med Hypotheses; 2020 Jul; 140():109782. PubMed ID: 32353743 [No Abstract] [Full Text] [Related]
9. Flavonoids against the SARS-CoV-2 induced inflammatory storm. Liskova A; Samec M; Koklesova L; Samuel SM; Zhai K; Al-Ishaq RK; Abotaleb M; Nosal V; Kajo K; Ashrafizadeh M; Zarrabi A; Brockmueller A; Shakibaei M; Sabaka P; Mozos I; Ullrich D; Prosecky R; La Rocca G; Caprnda M; Büsselberg D; Rodrigo L; Kruzliak P; Kubatka P Biomed Pharmacother; 2021 Jun; 138():111430. PubMed ID: 33662680 [TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory and Anti-Inflammatory Effects of Berberine in Lung Tissue and its Potential Application in Prophylaxis and Treatment of COVID-19. Majdalawieh AF; Yousef SM; Abu-Yousef IA; Nasrallah GK Front Biosci (Landmark Ed); 2022 May; 27(5):166. PubMed ID: 35638433 [TBL] [Abstract][Full Text] [Related]
11. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19. Al-Kuraishy HM; Al-Gareeb AI; Mostafa-Hedeab G; Kasozi KI; Zirintunda G; Aslam A; Allahyani M; Welburn SC; Batiha GE Front Immunol; 2021; 12():749291. PubMed ID: 34867978 [TBL] [Abstract][Full Text] [Related]
12. The shortcomings of tocilizumab in COVID-19. Tirupathi R; Bharathidasan K; Areti S; Kaur J; Salim S; Al-Tawfiq JA Infez Med; 2020 Dec; 28(4):465-468. PubMed ID: 33257619 [TBL] [Abstract][Full Text] [Related]
13. Proposed use of thalidomide for the cytokine storm of COVID-19. Goihman-Yahr M Clin Dermatol; 2020; 38(4):508. PubMed ID: 32972614 [No Abstract] [Full Text] [Related]
14. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities. Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855 [TBL] [Abstract][Full Text] [Related]
16. CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients. Hernandez-Cedeño M; Venegas-Rodriguez R; Peña-Ruiz R; Bequet-Romero M; Santana-Sanchez R; Penton-Arias E; Martinez-Donato G; Guillén-Nieto G; Dominguez-Horta MDC Cell Stress Chaperones; 2021 May; 26(3):515-525. PubMed ID: 33629254 [TBL] [Abstract][Full Text] [Related]
17. Modulating the host immune response to fight against COVID-19: Where are we in 2021? Hertanto DM; Sutanto H; Wiratama BS; Wungu CDK Virulence; 2021 Dec; 12(1):1732-1736. PubMed ID: 34224330 [No Abstract] [Full Text] [Related]
18. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm. Abdulrab S; Al-Maweri S; Halboub E Med Hypotheses; 2020 Oct; 143():109897. PubMed ID: 32505909 [No Abstract] [Full Text] [Related]
19. An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases. Filgueira LM; Cervantes JB; Lovelle OA; Herrera C; Figueredo C; Caballero JA; Sánchez N; Berrio J; Lorenzo G; Cepeda M; Ramos M; Saavedra D; Añe-Kouri AL; Mazorra Z; Leon K; Crombet T; Caballero A Immunotherapy; 2021 Mar; 13(4):289-295. PubMed ID: 33397150 [TBL] [Abstract][Full Text] [Related]
20. Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality. Moradian N; Gouravani M; Salehi MA; Heidari A; Shafeghat M; Hamblin MR; Rezaei N Eur Cytokine Netw; 2020 Sep; 31(3):81-93. PubMed ID: 33361013 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]